Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 3/20 | 0.37 |
| ▸ | NOS1 | P29475 | 3/20 | 0.37 |
| ▸ | NOS2 | P35228 | 3/20 | 0.37 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.34 |
| ▸ | NNMT | P40261 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13199572 | 0.77 | NOS3 (0.48) | NOS3NOS1NOS2ALDH1A1NNMT | |
| SCHEMBL15081248 | 0.77 | APP (0.39) | ALDH1A1MAP4K4PDPK1LMNATP53 | |
| SCHEMBL3590963 | 0.77 | GRM4 (0.41) | ALDH1A1MAP4K4NNMTCYP3A4PDPK1 | |
| SCHEMBL94027 | 0.77 | — | — | |
| SCHEMBL30154986 | 0.77 | — | — | |
| SCHEMBL20547368 | 0.76 | GABRP (0.41) | NOS3NOS1NOS2ALDH1A1NNMT | |
| Hydrochloric Acid SCHEMBL28718520 | 0.76 | NOS3 (0.46) | NOS3NOS1NOS2ALDH1A1NNMT | |
| SCHEMBL2791730 | 0.75 | ALDH1A1 (0.41) | NOS3NOS1NOS2ALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL27623348 | 0.75 | NOS3 (0.41) | NOS3NOS1NOS2UHRF1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4046885 | 0.75 | NOS3 (0.41) | NOS3NOS1NOS2UHRF1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| EP-3774739-B1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC (JP) | 2022-05-11 | — | — | EP | disclosed |
| US-8183275-B2 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183275-B2 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100204236-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-20100204236-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| WO-2008051405-A1 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204236-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | BRS3, GPR119, GIPR | NOS3 311/4885NOS1 1185/4885NOS2 1195/4885 |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | NOS3 1614/4885NOS1 2176/4885NOS2 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.